Bio-Techne Dividend Update: Essential Details Before the Ex-Dividend Date on May 19th, 2025
Generado por agente de IAAinvest Dividend Digest
jueves, 15 de mayo de 2025, 7:55 pm ET1 min de lectura
TECH--
Bio-Techne Corporation (TECH) has announced its latest dividend details, with the ex-dividend date set for May 19th, 2025. The dividend announcement was made on May 7th, 2025, revealing that shareholders will receive a cash dividend of $0.080 per share on May 30th, 2025. This payout remains consistent with the company's previous dividend issued on Feb 28th, 2025, which was also $0.080 per share. The average dividend over the last ten distributions has been higher, at $0.272 per share, indicating that the current dividend is comparatively lower.
Recently, Bio-TechneTECH-- has been actively engaging in strategic activities that could influence market performance and investor interest. The company is set to host a conference call on May 7th, 2025, to discuss its third-quarter fiscal 2025 financial results, highlighting recent developments in its operations. As of late, Bio-Techne has been showcasing its next-generation solutions in gene and cell therapy, emphasizing its leadership in advancing these technologies. Analysts have noted Bio-Techne's collaboration with Kytopen, focusing on an integrated cellular engineering workflow to expedite cell therapy manufacturing. This partnership underlines the company's commitment to enhancing scientific research and healthcare diagnostics.
Over the past week, Bio-Techne's stock price experienced a notable change, dropping to $47.86, marking a 7.27% decrease. This decline has sparked discussions regarding the company's market strategies and financial health. Since the last update, the corporation has also been awarded multiple G-Rex® Grants by ScaleReady, aimed at supporting researchers at prominent institutions like the University of Southern California and the Children's Hospital of Los Angeles. These initiatives reflect Bio-Techne's dedication to fostering innovation in biotechnology and supporting groundbreaking research.
As these developments unfold, investors should note that May 19th, 2025, is the crucial ex-dividend date. It marks the last opportunity for shareholders to purchase Bio-Techne's stock and qualify for the upcoming dividend. Any acquisition after this date will not entitle investors to the dividend for this period.
Recently, Bio-TechneTECH-- has been actively engaging in strategic activities that could influence market performance and investor interest. The company is set to host a conference call on May 7th, 2025, to discuss its third-quarter fiscal 2025 financial results, highlighting recent developments in its operations. As of late, Bio-Techne has been showcasing its next-generation solutions in gene and cell therapy, emphasizing its leadership in advancing these technologies. Analysts have noted Bio-Techne's collaboration with Kytopen, focusing on an integrated cellular engineering workflow to expedite cell therapy manufacturing. This partnership underlines the company's commitment to enhancing scientific research and healthcare diagnostics.
Over the past week, Bio-Techne's stock price experienced a notable change, dropping to $47.86, marking a 7.27% decrease. This decline has sparked discussions regarding the company's market strategies and financial health. Since the last update, the corporation has also been awarded multiple G-Rex® Grants by ScaleReady, aimed at supporting researchers at prominent institutions like the University of Southern California and the Children's Hospital of Los Angeles. These initiatives reflect Bio-Techne's dedication to fostering innovation in biotechnology and supporting groundbreaking research.
As these developments unfold, investors should note that May 19th, 2025, is the crucial ex-dividend date. It marks the last opportunity for shareholders to purchase Bio-Techne's stock and qualify for the upcoming dividend. Any acquisition after this date will not entitle investors to the dividend for this period.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios